Trial reportUnited European gastroenterology journal2026
Long-Term Colorectal Cancer Incidence After Adenoma and Serrated Polyp Removal: Results From the Colonprev Trial.
Trial report in United European gastroenterology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00906997 (Colorectal Cancer Screening in Average-risk Population), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Colorectal Cancer Screening in Average-risk Population: a Multicenter, Randomized Control Trial Comparing Immunochemical Fecal Occult Blood Testing Versus Colonoscopy.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundThe risk of colorectal cancer (CRC) after serrated polyp resection remains unclear, and current surveillance recommendations rely on limited evidence. We evaluated CRC incidence in individuals with advanced serrated lesions (ASL) detected at baseline colonoscopy and compared risk according to the most advanced lesion identified.
methodsParticipants undergoing colonoscopy within the COLONPREV trial (n = 8989) were included in this post hoc analysis. Individuals were classified according to the most advanced baseline lesion: no lesion, non-advanced adenoma, advanced adenoma, or ASL. The primary outcome was incident CRC. Cumulative incidence and hazard ratios (HR) were estimated using Cox proportional hazard models.
resultsAt baseline colonoscopy, serrated polyps were detected in 19.8% of participants, including ASL in 2.5%. Over a mean follow-up of 9.5 years, 44 CRC cases were diagnosed (cumulative incidence 0.49%; incidence rate 0.52 per 1000 person-years). The 10-year cumulative incidence was 0.27% in individuals without baseline lesions (n = 5496), 0.57% in those with non-advanced adenomas (n = 2091), 1.23% in advanced adenomas (n = 1218), and 1.09% in ASL (n = 184). In multivariable analysis, CRC risk was increased for non-advanced adenomas (HR 3.25, 95% CI 1.48-7.16), advanced adenomas (HR 9.77, 95% CI 4.24-22.50), and ASL (HR 6.37, 95% CI 1.42-28.54). Surveillance colonoscopy was associated with lower CRC incidence (HR 0.46, 95% CI 0.22-0.95 for one colonoscopy; HR 0.09, 95% CI 0.02-0.40 for ≥ 2 colonoscopies).
conclusionIn this screening cohort, ASL were associated with increased CRC risk in the range of advanced adenomas. These findings provide risk estimates relevant to post-polypectomy management. TRIAL REGISTRATION NUMBER: NCT00906997.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.